KPS-0373 ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 18 | 脊髄小脳変性症（多系統萎縮症を除く。） | 8 |
18. 脊髄小脳変性症（多系統萎縮症を除く。）
臨床試験数 : 71 / 薬物数 : 99 - (DrugBank : 30) / 標的遺伝子数 : 45 - 標的パスウェイ数 : 65
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02889302 (ClinicalTrials.gov) | November 15, 2016 | 31/8/2016 | An Additional Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) | An Additional Phase III Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) | Spinocerebellar Degeneration | Drug: KPS-0373;Drug: Placebo | Kissei Pharmaceutical Co., Ltd. | NULL | Completed | 20 Years | N/A | All | 203 | Phase 3 | Japan |
| 2 | NCT01970098 (ClinicalTrials.gov) | October 9, 2013 | 22/10/2013 | A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) | A Phase III Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) | Spinocerebellar Degeneration | Drug: KPS-0373, High dose;Drug: KPS-0373, Low dose;Drug: Placebo | Kissei Pharmaceutical Co., Ltd. | NULL | Completed | 20 Years | N/A | All | 374 | Phase 3 | Japan |
| 3 | NCT01970124 (ClinicalTrials.gov) | October 2013 | 22/10/2013 | A Long-Term Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) | Spinocerebellar Degeneration | Drug: KPS-0373, High dose;Drug: KPS-0373, Low dose | Kissei Pharmaceutical Co., Ltd. | NULL | Completed | 20 Years | N/A | Both | Phase 3 | Japan | ||
| 4 | NCT01970137 (ClinicalTrials.gov) | October 2013 | 22/10/2013 | A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) | Spinocerebellar Degeneration | Drug: KPS-0373, High dose;Drug: KPS-0373, Low dose | Kissei Pharmaceutical Co., Ltd. | NULL | Completed | 20 Years | N/A | Both | Phase 3 | Japan | ||
| 5 | NCT01970111 (ClinicalTrials.gov) | October 2013 | 22/10/2013 | An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) | Spinocerebellar Degeneration | Drug: KPS-0373, High dose;Drug: KPS-0373, Low dose | Kissei Pharmaceutical Co., Ltd. | NULL | Completed | 20 Years | N/A | Both | Phase 3 | Japan | ||
| 6 | NCT01384435 (ClinicalTrials.gov) | June 2011 | 23/6/2011 | A Phase II Double Blind Comparative Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) | A Randomized, Double Blind, Placebo-controlled Phase II Study of KPS-0373 in Patients With SCD | SCD | Drug: KPS-0373;Drug: Placebo | Kissei Pharmaceutical Co., Ltd. | NULL | Completed | 20 Years | N/A | Both | 200 | Phase 2 | Japan |
| 7 | NCT01004016 (ClinicalTrials.gov) | October 2009 | 27/10/2009 | A Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) | A Double-blind, Placebo-controlled, Crossover Study, Followed by Open-label Study of KPS-0373 in Patients With SCD | Spinocerebellar Degeneration | Drug: KPS-0373;Drug: Placebo | Kissei Pharmaceutical Co., Ltd. | NULL | Completed | 20 Years | N/A | Both | 20 | Phase 2 | Japan |
| 8 | NCT00863538 (ClinicalTrials.gov) | November 2004 | 16/3/2009 | Phase II Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) | An Open-label, Phase II Study of KPS-0373 in Patients With SCD | Spinocerebellar Degeneration | Drug: KPS-0373 | Kissei Pharmaceutical Co., Ltd. | NULL | Completed | 20 Years | N/A | Both | 40 | Phase 2 | Japan |